prevention of rheumatic fever
DESCRIPTION
PREVENTION OF RHEUMATIC FEVER. Dr. Animesh Mishra, DM (Delhi University) Associate Professor Department of Cardiology NEIGRIHMS Shillong-12. What is Acute Rheumatic fever ?. Infectious Immunological Genetic Collagen Vascular Disease Or an unidentified factor. ?. - PowerPoint PPT PresentationTRANSCRIPT
PREVENTION OFPREVENTION OF RHEUMATIC FEVERRHEUMATIC FEVER
Dr. Animesh Mishra, DM (Delhi University)Dr. Animesh Mishra, DM (Delhi University)Associate ProfessorAssociate Professor
Department of CardiologyDepartment of CardiologyNEIGRIHMSNEIGRIHMSShillong-12Shillong-12
What is Acute Rheumatic fever ?What is Acute Rheumatic fever ?
• Infectious
• Immunological
• Genetic
• Collagen Vascular Disease
• Or an unidentified factor.
Is It Possible to Prevent Rheumatic Is It Possible to Prevent Rheumatic Fever ?Fever ?
• Primordial Prevention
• Primary Prevention
• Secondary Prevention
Primordial preventionPrimordial prevention
Preventing the development of ‘risk factors’
Measures for Primordial Prevention
1- Improvement in Socio-Economic Status
2- Prevention of overcrowding
3- Availability of Prompt Medical care
4- Public Education
Primary PreventionPrimary Prevention
Measures for Primary Prevention Identification (GAS) Eradication (Penicillin) Susceptible individuals ? Anti Streptococcal Vaccine
Theoretical possibility at the community but Possible at individual level
Community level prevention Community level prevention ‘‘Sledge Hammer ApproachSledge Hammer Approach’ ’
3%-20% of sore throat are GAS
.3% of GAS sore throat result in RF
90% of Patients of RF develops RHD
10000 Sore throats
300 2000
.
.3% RF1 6
90%RHD1 5
10000
3%-20% GAS
Identification and Eradication of Identification and Eradication of GAS -Not Feasible at community GAS -Not Feasible at community
levellevel 1- Asymptomatic sore throat 2- Diagnosis at mass level 3- Identification Methods not 100%senstive and specific 4- Route of infection 5- Non compliance with the oral Treatment 6- Treatment failure (Penicillin failure)
Susceptible individualsSusceptible individuals
• HLA-D 1,2,3,4
• HLA –D 8/17 Indian population
• B cell alloantigen
Results can not be utilized at community level
Rheumatic VaccineRheumatic Vaccine
Strain specific M-Protein
Caveats 1-Hundreds of Strains 2- Fast mutation rate 3- Virulent GAS may not produce M-Protein
Polyvalent vaccines- Tried, but not successful
Conserved C-Terminus of M-protein
C-5a Peptidase
Fibro nectin surface binding Protein (sfb-1)
Chemaric peptide J8
Polysaccharide conjugated with protein
Health Education (5-16 years)
Education by Parents
Teachers
All India Radio
Doordarshan
NICs, CICs
Health Education (5-16 years)
Education by Parents
Teachers
All India Radio
Doordarshan
NICs, CICs
Secondary PreventionSecondary PreventionSecondary Attack Rate -50%Secondary Attack Rate -50%
• Penicillin Prophylaxis – Every 2-3 weeks (Depending upon the Age, Wt, Muscle mass ) Duration of prophylaxis – LIFE LONG 10Yrs/ Adulthood 5Yrs/ 18Yrs. 1YrsAnaphylactic Shock: 1: 1000000= 10
5
Secondary Prevention cannot reduce the burden of RHDSS